Get the Stockscreener App
27.42
1.54%
-0.43
Pre-market:
27.26
-0.16
-0.58%
Mersana Therapeutics Inc stock is traded at $27.42, with a volume of 57,599.
It is down -1.54% in the last 24 hours and up +236.03% over the past month.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.
See More
Previous Close:
$27.85
Open:
$27.9
24h Volume:
57,599
Relative Volume:
0.53
Market Cap:
$137.07M
Revenue:
$34.77M
Net Income/Loss:
$-74.04M
P/E Ratio:
-3.4208
EPS:
-8.0157
Net Cash Flow:
$-79.76M
1W Performance:
-0.44%
1M Performance:
+236.03%
6M Performance:
+197.24%
1Y Performance:
-51.68%
1-Day Range:
$27.31
$28.36
1-Week Range:
$27.30
$28.36
52-Week Range:
$5.21
$70.73
Mersana Therapeutics Inc Stock (MRSN) Company Profile
Name
Mersana Therapeutics Inc
Sector
Industry
Phone
617-498-0020
Address
840 MEMORIAL DRIVE, CAMBRIDGE
Compare MRSN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRSN
Mersana Therapeutics Inc
|
27.42 | 139.22M | 34.77M | -74.04M | -79.76M | -8.0157 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Mersana Therapeutics Inc Stock (MRSN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-06-25 | Initiated | William Blair | Outperform |
| Nov-15-24 | Resumed | Citigroup | Buy |
| Mar-19-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Feb-29-24 | Upgrade | BTIG Research | Neutral → Buy |
| Feb-29-24 | Upgrade | Guggenheim | Neutral → Buy |
| Feb-29-24 | Upgrade | Wedbush | Neutral → Outperform |
| Dec-04-23 | Upgrade | Citigroup | Neutral → Buy |
| Jul-28-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jul-27-23 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-27-23 | Downgrade | Citigroup | Buy → Neutral |
| Jul-27-23 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-27-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Jul-27-23 | Downgrade | Truist | Buy → Hold |
| Jul-27-23 | Downgrade | Wedbush | Outperform → Neutral |
| Jun-16-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Jun-15-23 | Initiated | Guggenheim | Buy |
| Mar-16-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-20-23 | Initiated | Citigroup | Buy |
| Nov-21-22 | Initiated | Truist | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Aug-30-21 | Initiated | H.C. Wainwright | Buy |
| Mar-31-21 | Initiated | Credit Suisse | Neutral |
| Dec-03-20 | Initiated | Stifel | Buy |
| Sep-29-20 | Resumed | JP Morgan | Neutral |
| Apr-29-20 | Initiated | BTIG Research | Buy |
| Jan-21-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-11-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Nov-14-18 | Upgrade | Leerink Partners | Mkt Perform → Outperform |
| May-08-18 | Initiated | Robert W. Baird | Outperform |
| Mar-19-18 | Downgrade | JP Morgan | Overweight → Neutral |
View All
Mersana Therapeutics Inc Stock (MRSN) Latest News
Day One to buy Mersana Therapeutics for $25/share upfront - MSN
Is Mersana Therapeutics Inc. (0M4) stock prepared for digital transitionRate Hike & Daily Growth Stock Investment Tips - Newser
Can Mersana Therapeutics Inc. (0M4) stock stage a strong rebound this quarter - Newser
Can Mersana Therapeutics Inc. (0M4) stock sustain breakout momentumJuly 2025 PreEarnings & High Accuracy Investment Entry Signals - Newser
Why Mersana Therapeutics Inc. (0M4) stock could be next leaderJuly 2025 Opening Moves & Community Consensus Stock Picks - Newser
How Mersana Therapeutics Inc. (0M4) stock compares with top peersQuarterly Earnings Summary & Fast Gain Stock Trading Tips - Newser
Will Mersana Therapeutics Inc. (0M4) stock attract long term capital inflowsJuly 2025 Review & Consistent Income Trade Ideas - Newser
Will Mersana Therapeutics Inc. (0M4) stock deliver compounding returnsQuarterly Trade Report & Breakout Confirmation Alerts - Newser
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Given Consensus Recommendation of "Reduce" by Brokerages - MarketBeat
Options Flow: How Mersana Therapeutics Inc. (0M4) stock compares with market leadersJuly 2025 Setups & Daily Technical Forecast Reports - BỘ NỘI VỤ
How Mersana’s Acquisition Is Changing the Story and Analyst Outlook for Investors - Yahoo Finance
Halper Sadeh LLC Encourages SEMR, EXAS, MRSN Shareholders to Contact the Firm to Discuss Their Rights - Sahm
HAPPY THANKSGIVING AND INVESTOR ALERT: The M&A Class Action Firm Continues to Investigate the MergerEXAS, SEE, CDTX, and MRSN - The Malaysian Reserve
Halper Sadeh LLC Encourages SEE, EXAS, MRSN Shareholders to Contact the Firm to Discuss Their Rights - GlobeNewswire Inc.
Is Mersana Therapeutics Inc. (0M4) stock a buy before new product rolloutJuly 2025 Rallies & Risk Controlled Daily Plans - BỘ NỘI VỤ
ENN Energy Holdings Announces Conditional Privatization Proposal - The Globe and Mail
683 Capital Management, LLC Increases Stake in Mersana Therapeutics Inc. - GuruFocus
Can Mersana Therapeutics Inc. (0M4) stock test all time highsJuly 2025 Macro Moves & Free Reliable Trade Execution Plans - newser.com
Will Mersana Therapeutics Inc. stock outperform Dow Jones indexJuly 2025 Trade Ideas & Safe Capital Growth Stock Tips - newser.com
Is Mersana Therapeutics Inc. (0M4) stock testing key supportEarnings Risk Report & AI Driven Stock Reports - newser.com
Does Mersana Therapeutics Inc. qualify in momentum factor screeningShort Setup & Low Drawdown Momentum Ideas - newser.com
Why Mersana Therapeutics Inc. stock remains a top recommendationEarnings Miss & Free Reliable Trade Execution Plans - newser.com
Earnings visualization tools for Mersana Therapeutics Inc.2025 Risk Factors & Safe Swing Trade Setup Alerts - newser.com
Will Mersana Therapeutics Inc. stock benefit from infrastructure spending2025 Analyst Calls & Safe Entry Point Alerts - newser.com
How Mersana Therapeutics Inc. (0M4) stock reacts to weak economyTrade Exit Summary & Safe Capital Growth Tips - newser.com
Detecting price anomalies in Mersana Therapeutics Inc. with AIWeekly Trade Report & Low Risk Entry Point Guides - newser.com
Using data filters to optimize entry into Mersana Therapeutics Inc.Weekly Investment Summary & Low Risk Entry Point Guides - newser.com
Mersana Therapeutics Inc Stock (MRSN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):